| Title | Anti-VEGFR, PDGFR, and CSF1R tyrosine kinase inhibitor CM082 (X-82) in combination with everolimus for treatment of metastatic renal cell carcinoma: a phase 1 clinical trial |
| Authors | Yan, Xieqiao Sheng, Xinan Tang, Bixia Chi, Zhihong Cui, Chuanliang Si, Lu Mao, Li Li Lian, Bin Li, Siming Zhou, Li Wang, Xuan Bai, Xue Kong, Yan Dai, Jie Guo, Jun |
| Affiliation | Peking Univ Canc Hosp & Inst, Minist Educ, Collaborat Innovat Ctr Canc Med, Key Lab Carcinogenesis & Translat Res,Dept Renal, Beijing, Peoples R China. Collaborat Innovat Ctr Canc Med, Beijing, Peoples R China. |
| Issue Date | 2017 |
| Publisher | LANCET ONCOLOGY |
| Citation | LANCET ONCOLOGY.2017,18,S8-S8. |
| URI | http://hdl.handle.net/20.500.11897/471009 |
| ISSN | 1470-2045 |
| Indexed | SCI(E) |
| Appears in Collections: | 北京肿瘤医院 |
